Funds for immunotherapy treatment

I reported previously (three times) on Israel’s Enlivex and its Allocetra / Apocell treatment to prevent Graft vs Host Disease – a common problem after bone marrow transplants.  Elivex has just received $8 million of funding which will help it progress to Phase 3 trials.,7340,L-3721734,00.html

This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *